Abstract
Objective: The aims and objectives of this study to examine the general population one year later following immunization for changes in anti-SARS-CoV-2 IgG levels. Methodology: The study enrolled 18,610 individuals, including rural and urban areas. The quantities of IgG antibodies were determined using an ELISA. Results: At 5–8 months following complete immunization, both vaccines produced comparable amounts of anti-SARS-CoV-2 IgG. On the other hand, BBIBP-CorV had a much lower IgG concentration. Anti-SARS-CoV-2 IgG levels in a large cohort of volunteers increased nine months after vaccination, indicating asymptomatic infection. Anti-SARS-CoV-2 IgG antibody levels were significantly higher following the booster dose than following the second dose. Antibodies began to build approximately five days after the booster dosage injection and peaked around the fourteenth day. Conclusion: Cut-off dates for the effectiveness of mRNA and vector vaccines appear to be 8–9 months and 5–6 months following vaccination, respectively. With the potential to have a significant impact on the virus's ongoing transmission, providing a booster dose was a brilliant idea. Key words: SARS-CoV-2, IgG antibody, mRNA.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
